Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Current Liabilities (2016 - 2026)

Insight Molecular Diagnostics' Total Current Liabilities history spans 7 years, with the latest figure at $12.1 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 65.98% to $12.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.1 million, a 65.98% increase, with the full-year FY2025 number at $12.1 million, up 65.98% from a year prior.
  • Total Current Liabilities hit $12.1 million in Q4 2025 for Insight Molecular Diagnostics, up from $7.7 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for IMDX hit a ceiling of $19.8 million in Q2 2021 and a floor of $6.7 million in Q2 2025.
  • Historically, Total Current Liabilities has averaged $10.5 million across 5 years, with a median of $9.6 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: surged 189.02% in 2021 and later crashed 45.83% in 2023.
  • Tracing IMDX's Total Current Liabilities over 5 years: stood at $14.1 million in 2021, then decreased by 14.26% to $12.1 million in 2022, then plummeted by 40.57% to $7.2 million in 2023, then rose by 1.13% to $7.3 million in 2024, then surged by 65.98% to $12.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for IMDX at $12.1 million in Q4 2025, $7.7 million in Q3 2025, and $6.7 million in Q2 2025.